Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy

FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease

AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II...

ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and...

Biokin Pharma announces approval of Iza-bren in China for the treatment of recurrent/metastatic ESCC

U.S. FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of...

China’s NMPA administration accepts Biologics License Application for PADCEV plus Keytruda in Muscle-Invasive Bladder Cancer

Hengrui ADC innovative drug Ruikang Trastuzumab new indication marketing application accepted and included in priority...

InnoCare Pharma announced that the first patient dosing in the clinical trial of ICP-B208, its...